Astellas Pharma Inc. (Tokyo:4503) (Astellas) and FibroGen, Inc. (FibroGen) announced today the initiation of a Phase 2 clinical study in Japan of ASP1517/FG-4592 for treatment of anemia associated with chronic kidney disease (CKD) in patients on dialysis.
http://www.news-medical.net/news/20130731/FibroGen-and-Astellas-initiates-Phase-2-study-of-ASP1517FG-4592-for-treatment-of-anemia-linked-with-CKD.aspx